Last update 23 Jan 2025

Immuno Cure 3 Limited

Overview

Tags

Respiratory Diseases
Infectious Diseases
DNA vaccine
Prophylactic vaccine

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Disease DomainCount
Infectious Diseases1
Top 5 Drug TypeCount
DNA vaccine1
Prophylactic vaccine1

Related

1
Drugs associated with Immuno Cure 3 Limited
COVID-2019 DNA vaccine (Immuno Cure 3)
Target-
Mechanism
Immunostimulants
Active Org.
The University of Hong KongThe University of Hong Kong [+1]
Originator Org.
The University of Hong KongThe University of Hong Kong
Active Indication
COVID-19
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Immuno Cure 3 Limited
NCT05904054
/ Active, not recruitingPhase 2
An Open-label and Single-center Phase IIa Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 DNA Vaccine (ICCOV) in Healthy Subjects Aged 18-75 Years
NCT05102643
/ Unknown statusPhase 1
A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19 in Healthy Adults
100 Clinical Results associated with Immuno Cure 3 Limited
Login to view more data
0 Patents (Medical) associated with Immuno Cure 3 Limited
Login to view more data
100 Deals associated with Immuno Cure 3 Limited
Login to view more data
100 Translational Medicine associated with Immuno Cure 3 Limited
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
COVID-2019 DNA vaccine (Immuno Cure 3)
COVID-19
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free